卡维地洛和美托洛尔治疗慢性心力衰竭疗效的Meta分析

Meta-Analysis for The Effects of Carvedilol and Metoprolol on Treatment of Chronic Heart Failure

目的:比较β-受体阻滞剂卡维地洛与美托洛尔对治疗慢性心力衰竭的临床疗效。方法:检索国内关于卡维地洛与美托洛尔对照研究慢性心力衰竭的文献,应用荟萃分析(Meta)对查阅并筛选得到15篇进行评估。结果:卡维地洛治疗心力衰竭的显效率比美托洛尔高(OR=1.55,95%CI为1.22～1.96,P=0.000 3);卡维地洛治疗心力衰竭的有效率比美托洛尔高(OR=1.14,95%CI为0.91～1.43,P=0.25);卡维地洛治疗心力衰竭的不良反应发生率比美托洛尔低(OR=0.61,95%CI为0.33～1.10,P=0.10)。结论:卡维地洛的临床有效率显著高于美托洛尔。

Objectire： To compare the clinical curative effect between β- blockers carvedilol and metoprolol in treating chronic heart failure. Methods： To retrieve the domestic literatures about Carvedilol and Metoprolol control study on chronic heart failure and apply Meta- analysis to evaluate the consulted and screened 15 papers. Results：Carvedilol significantly better than Metoprolol for the treatment in heart failure（ OR = 1. 55,95% CI 为 1. 22 ～1. 96,P = 0. 0003）; Carvedilol showed higher efficacy than Metoprolol for the treatment in heart failure（ OR =1. 14,95% CI 为 0. 91 ～ 1. 43,P = 0. 25）; In treatment of heart failure,the incidence of adverse reaction for Carvedilol is lower than Metoprolol. Conclusions： The clinical effectiveness of Carvedilol is significantly higher than that of Metoprolol.